Literature DB >> 23428899

Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.

Belinda Berdien1, Henrike Reinhard, Sabrina Meyer, Stefanie Spöck, Nicolaus Kröger, Djordje Atanackovic, Boris Fehse.   

Abstract

Adoptive transfer of T lymphocytes equipped with tumor-antigen specific T-cell receptors (TCRs) represents a promising strategy in cancer immunotherapy, but the approach remains technically demanding. Using influenza virus (Flu)-specific T-cell responses as a model system we compared different methods for the generation of T-cell clones and isolation of antigen-specific TCRs. Altogether, we generated 12 CD8(+) T-cell clones reacting to the Flu matrix protein (Flu-M) and 6 CD4(+) T-cell clones reacting to the Flu nucleoprotein (Flu-NP) from 4 healthy donors. IFN-γ-secretion-based enrichment of antigen-specific cells, optionally combined with tetramer staining, was the most efficient way for generating T-cell clones. In contrast, the commonly used limiting dilution approach was least efficient. TCR genes were isolated from T-cell clones and cloned into both a previously used gammaretroviral LTR-vector, MP91 and the novel lentiviral self-inactivating vector LeGO-MP that contains MP91-derived promotor and regulatory elements. To directly compare their functional efficiencies, we in parallel transduced T-cell lines and primary T cells with the two vectors encoding identical TCRs. Transduction efficiencies were approximately twice higher with the gammaretroviral vector. Secretion of high amounts of IFN-γ, IL-2 and TNF-α by transduced cells after exposure to the respective influenza target epitope proved efficient specificity transfer of the isolated TCRs to primary T-cells for both vectors, at the same time indicating superior functionality of MP91-transduced cells. In conclusion, we have developed optimized strategies to obtain and transfer antigen-specific TCRs as well as designed a novel lentiviral vector for TCR-gene transfer. Our data may help to improve adoptive T-cell therapies.

Entities:  

Keywords:  T-cell receptor (TCR); TCR gene therapy; adoptive immunotherapy; gene transfer; influenza antigen; lentiviral vectors

Mesh:

Substances:

Year:  2013        PMID: 23428899      PMCID: PMC3901808          DOI: 10.4161/hv.24051

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  45 in total

1.  Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements.

Authors:  F Ayuk; Z Li; K Kühlcke; C Lindemann; U Schade; H G Eckert; A Zander; B Fehse
Journal:  Gene Ther       Date:  1999-10       Impact factor: 5.250

2.  Design of 5' untranslated sequences in retroviral vectors developed for medical use.

Authors:  M Hildinger; K L Abel; W Ostertag; C Baum
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

4.  Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex.

Authors:  Mirjam H M Heemskerk; Renate S Hagedoorn; Menno A W G van der Hoorn; Lars T van der Veken; Manja Hoogeboom; Michel G D Kester; Roel Willemze; J H Frederik Falkenburg
Journal:  Blood       Date:  2006-09-12       Impact factor: 22.113

5.  Designer T cells by T cell receptor replacement.

Authors:  Daniel Sommermeyer; Julia Neudorfer; Monika Weinhold; Matthias Leisegang; Boris Engels; Elfriede Noessner; Mirjam H M Heemskerk; Jehad Charo; Dolores J Schendel; Thomas Blankenstein; Helga Bernhard; Wolfgang Uckert
Journal:  Eur J Immunol       Date:  2006-11       Impact factor: 5.532

6.  Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes.

Authors:  Boris Engels; Elfriede Noessner; Bernhard Frankenberger; Thomas Blankenstein; Dolores J Schendel; Wolfgang Uckert
Journal:  Hum Gene Ther       Date:  2005-07       Impact factor: 5.695

7.  Generation of T-cell receptor retrogenic mice.

Authors:  Jeff Holst; Andrea L Szymczak-Workman; Kate M Vignali; Amanda R Burton; Creg J Workman; Dario A A Vignali
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

8.  Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.

Authors:  Cyrille J Cohen; Yangbing Zhao; Zhili Zheng; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

9.  Facilitating matched pairing and expression of TCR chains introduced into human T cells.

Authors:  Jürgen Kuball; Michelle L Dossett; Matthias Wolfl; William Y Ho; Ralf-Holger Voss; Carla Fowler; Philip D Greenberg
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

10.  Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

Authors:  Cyrille J Cohen; Yong F Li; Mona El-Gamil; Paul F Robbins; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

View more
  4 in total

Review 1.  Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy.

Authors:  Gang Xin; David M Schauder; Ryan Zander; Weiguo Cui
Journal:  Immunotherapy       Date:  2017-09       Impact factor: 4.196

2.  Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections.

Authors:  Tanja A Stief; Theresa Kaeuferle; Thomas R Müller; Michaela Döring; Lena M Jablonowski; Kilian Schober; Judith Feucht; Kevin M Dennehy; Semjon Willier; Franziska Blaeschke; Rupert Handgretinger; Peter Lang; Dirk H Busch; Tobias Feuchtinger
Journal:  Mol Ther       Date:  2021-05-29       Impact factor: 11.454

3.  Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma.

Authors:  Sara Yousef; Johanna Heise; Nesrine Lajmi; Katrin Bartels; Nicolaus Kröger; Tim Luetkens; Djordje Atanackovic
Journal:  J Transl Med       Date:  2015-06-20       Impact factor: 5.531

4.  Genome-wide off-target analyses of CRISPR/Cas9-mediated T-cell receptor engineering in primary human T cells.

Authors:  Theresa Kaeuferle; Tanja A Stief; Stefan Canzar; Nayad N Kutlu; Semjon Willier; Dana Stenger; Paulina Ferrada-Ernst; Nicola Habjan; Annika E Peters; Dirk H Busch; Tobias Feuchtinger
Journal:  Clin Transl Immunology       Date:  2022-01-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.